Mepolizumab in the treatment of severe eosinophilic asthma: “results from a physician in the field”

We would like to report our real-world results of using mepolizumab in patients with severe eosinophilic asthma in an office environment. This was a retrospective study; written permission was granted by all patients to use results of their treatment with mepolizumab, a monoclonal antibody directed against the interleukin 5 cytokine.

https://ift.tt/2J9vCyk